RxDoctor Payments Data

David Yi, MD

Family Medicine · Trophy Club, TXNPI 1700899044

Payments from drug & device makers

$7,954in general payments, 2019–2025

Across 419 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$772
  • Novo Nordisk$673
  • GSK$513
  • Antares Pharma, Inc.$362
  • Lilly USA, LLC$324
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,87999%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,954 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$48,194
Medicare patients
133
Services billed
819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide101$114,925
OzempicSemaglutide45$53,222
JardianceEmpagliflozin17$26,702
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$25,139
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$11,170
XareltoRivaroxaban11$8,527
Liothyronine Sodium76$3,417
Rosuvastatin Calcium274$3,089
Ezetimibe83$1,488
Levothyroxine Sodium119$1,198
Losartan Potassium88$641
Duloxetine Hcl34$608
SynthroidLevothyroxine Sodium17$608
Cefdinir21$596
Atorvastatin Calcium50$507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$324$114,925101 claims
Novo NordiskOzempic$673$53,22245 claims
GSKTrelegy Ellipta, Anoro Ellipta$513$36,31031 claims
Boehringer IngelheimJardiance$242$26,70217 claims
AbbVieSynthroid$772$60817 claims
Acella Pharmaceuticals, LLCNp Thyroid$23$32611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Trophy Club

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →